These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 23859201)

  • 1. Interview with Celia Schiffer.
    Schiffer C
    Future Med Chem; 2013 Jul; 5(11):1193-7. PubMed ID: 23859201
    [No Abstract]   [Full Text] [Related]  

  • 2. Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus.
    Bagaglio S; Messina E; Uberti-Foppa C; Merli M; Torre LD; Lazzarin A; Hasson H; Morsica G
    J Antimicrob Chemother; 2013 Jun; 68(6):1448-50. PubMed ID: 23390206
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibitors of HIV proteinase.
    Martin JA; Redshaw S; Thomas GJ
    Prog Med Chem; 1995; 32():239-87. PubMed ID: 8577919
    [No Abstract]   [Full Text] [Related]  

  • 4. HIV protease inhibitors.
    Winslow DL; Otto MJ
    AIDS; 1995; 9 Suppl A():S183-92. PubMed ID: 8819585
    [No Abstract]   [Full Text] [Related]  

  • 5. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
    Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
    J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
    Tsantrizos YS
    Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update of the drug resistance mutations in HIV-1: 2004.
    Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
    Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
    [No Abstract]   [Full Text] [Related]  

  • 8. HIV-protease inhibitors.
    Flexner C
    N Engl J Med; 1998 Apr; 338(18):1281-92. PubMed ID: 9562584
    [No Abstract]   [Full Text] [Related]  

  • 9. Advances in non-peptidomimetic HIV protease inhibitors.
    Pang X; Liu Z; Zhai G
    Curr Med Chem; 2014 Jun; 21(17):1997-2011. PubMed ID: 24533811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of HIV protease inhibitors as anti AIDS drugs: molecular design based on substrate transition state].
    Kiso Y
    Tanpakushitsu Kakusan Koso; 1998 May; 43(6):725-33. PubMed ID: 9612066
    [No Abstract]   [Full Text] [Related]  

  • 11. Update on HIV protease inhibitors.
    Vella S
    AIDS Clin Care; 1995 Oct; 7(10):79-82, 88. PubMed ID: 11362832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 protease folding and the design of drugs which do not create resistance.
    Broglia R; Levy Y; Tiana G
    Curr Opin Struct Biol; 2008 Feb; 18(1):60-6. PubMed ID: 18160276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Among the devils in the details are protease sequence, susceptibility, and structure in CRF02_AG viruses.
    Katzenstein D; Ogden R
    Clin Infect Dis; 2005 Jul; 41(2):252-4. PubMed ID: 15983924
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness of commercial inhibitors against subtype F HIV-1 protease.
    Krauchenco S; Martins NH; Sanches M; Polikarpov I
    J Enzyme Inhib Med Chem; 2009 Jun; 24(3):638-45. PubMed ID: 18825538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational drug design and HIV: hopes and limitations.
    Goody RS
    Nat Med; 1995 Jun; 1(6):519-20. PubMed ID: 7585113
    [No Abstract]   [Full Text] [Related]  

  • 16. Analysis of sequence configurations of the PKR-interacting HCV proteins from plasma and PBMC as predictors of response to interferon-alpha and ribavirin therapy in HIV-coinfected patients.
    Bolcic F; Bull L; Martinez L; Reynoso R; Salomon H; Arduino R; Barnett B; Quarleri J
    Intervirology; 2008; 51(4):261-4. PubMed ID: 18824873
    [No Abstract]   [Full Text] [Related]  

  • 17. Synthesis and evaluation of A-seco type triterpenoids for anti-HIV-1protease activity.
    Wei Y; Ma CM; Hattori M
    Eur J Med Chem; 2009 Oct; 44(10):4112-20. PubMed ID: 19493591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [HIV-1 protease inhibitors: cell metabolism and drug resistance (review)].
    Bobkova MR
    Ter Arkh; 2008; 80(10):77-80. PubMed ID: 19105421
    [No Abstract]   [Full Text] [Related]  

  • 19. An interview with Charles A.B. Boucher, MD, PhD. Interview by Mark Mascolini.
    Boucher CA
    J Int Assoc Physicians AIDS Care; 1995 Nov; 1(10):30-5. PubMed ID: 11362972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 protease: structure, dynamics, and inhibition.
    Louis JM; Ishima R; Torchia DA; Weber IT
    Adv Pharmacol; 2007; 55():261-98. PubMed ID: 17586318
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.